Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Jennifer L. GuerrieroDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, Massachusetts 02115, USAAlaba SotayoDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, Massachusetts 02115, USAHolly PonichteraDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, Massachusetts 02115, USAJessica A. CastrillonDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, Massachusetts 02115, USAAlexandra L. PourziaDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, Massachusetts 02115, USASara SchadDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, Massachusetts 02115, USAShawn F. JohnsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, Massachusetts 02115, USARuben D. CarrascoDepartment of Pathology, Brigham and Women's Hospital, 75 Francis Street, Massachusetts 02115, USASuzan LazoDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, Massachusetts 02115, USARoderick T. BronsonDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts 02115, USAScott DavisGlaxoSmithKline, 200 Technology Square Suite 602, Cambridge, Massachusetts 02139, USAMercedes LoberaGlaxoSmithKline, 200 Technology Square Suite 602, Cambridge, Massachusetts 02139, USAMichael A. NolanGlaxoSmithKline, 200 Technology Square Suite 602, Cambridge, Massachusetts 02139, USAAnthony LetaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, Massachusetts 02115, USA
2017en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0